Effects of liraglutide and sibutramine on food intake,palatability, body weight and glucose tolerance in the gubra DIO-rats

摘要

Aim:To validate the gubra DIO-rats as a useful animal model of human obesity.Methods:The gubra diet-induced obesity (DIO) rat model was based on male Sprague-Dawley rats with ad libitum access to regular chow and a palatable diet rich in fat and sugar.To evaluate the versatility of the gubra DlO-rats as a valid model of human obesity syndrome,the efficacy of 2 weight loss compounds liraglutide and sibutramine with different mechanisms of action were examined in 7-month-old gubra DIO-rats.Liraglutide(200 μg/kg,sc) was administered bi-daily,and sibutramine (5 mg/kg,po) was administered once daily for 23 d.Results:Both the compounds effectively reduced the food intake,body weight and total fat mass as measured by nuclear magnetic resonance.Whereas the 5-HT reuptake inhibitor/5-HT receptor agonist sibutramine reduced the intake of both chow and the gubradiet,the GLP-1 analogue liraglutide predominantly reduced the intake of the highly palatable diet,indicating a shift in food preference.Sibutramine lowered the insulin sensitivity index,primarily via reductions in glucose-stimulated insulin secretion.Conclusion:This animal model responds well to 2 weight loss compounds with different mechanisms of action.Moreover,the gubra DIO-rat can be particularly useful for the testing of compounds with potential effects on diet preference.